Shattuck Labs (STTK) Director Option Grant — 66,300 Shares, $0.99 Strike

Rhea-AI Filing Summary

Shattuck Labs director Dr. Daniel G. Baker received a stock option award for 66,300 shares of common stock with a $0.99 exercise price on 08/28/2025. The option vests in three equal annual installments beginning on the grant date and is exercisable through 08/28/2035, subject to continued service. The Form 4 was filed on 09/02/2025 and signed by an attorney-in-fact. The disclosure shows an executive compensation action that increases potential common shares outstanding if exercised and ties the director's future economic incentive to the company's stock performance.

Positive

• Alignment with shareholders: Option ties director compensation to share performance
• Retention incentive: Three-year vesting schedule encourages continued service

Negative

• Potential dilution: Exercise of 66,300 options would increase shares outstanding
• No performance conditions disclosed: Vesting is time-based rather than tied to company performance

Insights

Corporate Governance Expert

TL;DR: Director grant aligns interests but creates potential dilution; standard long-term retention structure.

The award is a typical service-based option designed to retain a director and align incentives with shareholders. Vesting over three years with a ten-year exercise window is within market norms for smaller public companies. The exercise price of $0.99 establishes the strike relative to the market at grant, and full exercise would add 66,300 shares to outstanding common stock, which investors should quantify versus total shares outstanding to assess dilution.

Compensation Analyst

TL;DR: Compensation appears routine and time-based, not explicitly performance-contingent.

The option vests based solely on continued service, not explicit performance metrics, indicating retention-focused pay. The ten-year term gives flexibility for exercise timing. Materiality depends on company size; absent share-count context or grant value, the grant is routine disclosure rather than a material corporate event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baker Daniel G.

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TX 78701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.99	08/28/2025		A		66,300		(1)	08/28/2035	Common Stock	66,300	$0	66,300	D

Explanation of Responses:

1. This option represents the right to purchase a total of 66,300 shares of the Issuer's common stock, and vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, subject to the Reporting Person's continued service to the Issuer.

	/s/ Andrew R. Neill, Attorney-in-Fact for Dr. Daniel G. Baker	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did STTK director Dr. Daniel G. Baker receive on 08/28/2025?

He received a stock option to purchase 66,300 shares of Shattuck Labs common stock at an exercise price of $0.99 per share.

When does the option granted to the STTK director vest and expire?

The option vests in three equal annual installments beginning 08/28/2025 and is exercisable through 08/28/2035.

Who filed the Form 4 for the STTK transaction and when?

The Form 4 was filed and signed by Andrew R. Neill, Attorney-in-Fact on 09/02/2025.

Is the reported option grant performance-based?

No performance conditions are disclosed; the option vests based on continued service over three years.

How might this Form 4 affect STTK shareholders?

If exercised, the 66,300 shares would dilute existing holders; the materiality depends on STTK's total shares outstanding, which is not provided in this filing.